MedTrace Logo

Immunoregulatory Effects of Immunoglobulin Induction Therapy in Renal Transplant Recipients

NCT00176059 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2007-05-10

No results posted yet for this study

Summary

The aim of this randomized prospective study in renal transplant recipients is to investigate immunological short and long-term effects of an IVIG induction therapy.

Furthermore clinical endpoints (patient and graft survival, incidence of acute and chronic rejection, infectious diseases and graft function) up to three years posttransplant will be analyzed.

Conditions

  • Renal Failure, Chronic
  • Renal Transplantation

Interventions

DRUG

intravenous immunoglobulins (IVIG)

PROCEDURE

kidney transplantation

Sponsors & Collaborators

  • Heidelberg University

    collaborator OTHER

  • Astellas Pharma Inc

    collaborator INDUSTRY

  • Hoffmann-La Roche

    collaborator INDUSTRY

  • Aventis Pharmaceuticals

    collaborator INDUSTRY

  • University of Giessen

    lead OTHER

Principal Investigators

  • Rolf Weimer, Prof. Dr. · Department of Internal Medicine, University of Giessen, Giessen, Germany

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
14 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-10-31
Completion
2006-05-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00176059 on ClinicalTrials.gov